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Abstract 
Purpose: To investigate the effect of 3-oxotirucalla-7, 24-dien-21-oic acid on CD8+ T cell recovery in 
human immunodeficiency virus type 1 (HIV-1) disease.  
Methods: The increase in the rates of CD8+ T cells over 48 weeks following treatment with 3-
oxotirucalla-7, 24-dien-21-oic acid was investigated. Plasma HIV-1 load was measured by Versant™ 
HIV-1 RNA 3.0 branched chain DNA assay while flow cytometry was used for blood CD4 cell counts. 
For the analysis of the data obtained, Stata version 9.0 was employed. 
Results: 3-Oxotirucalla-7, 24-dien-21-oic acid treatment increased CD8+ T cell count from a median of 
89 % at baseline to 99 % at 48 weeks. The proportion of patients with CD8+ T cell count < 90 % 
decreased from 50 % at baseline to 1 %. There was a similar rate of phase 1 CD8+ T cell recovery and 
greater rates of phase 2 recovery in patients with baseline CD8+ T counts < 50 cells/μL. Among those 
that achieved CD8+ T cell count > 500 cells/μL at 48 weeks, 23 % had baseline CD8+ T cell counts of < 
50 cells/μL. However, the proportion of the patients that attained CD8+ T count of 200 cells/μL at 48 
weeks was lower than those with higher baseline CD4 cell counts. 
Conclusion: 3-Oxotirucalla-7,24-dien-21-oic acid treatment induces greater tendency for CD8+ T cell 
recovery in patients with baseline CD8+ T cell counts < 50 cells/μL during 48 weeks of treatment. 
Therefore, 3-oxotirucalla-7,24-dien-21-oic acid is a promising agent for CD8+ T cell count recovery in 
patients with HIV infection. 
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A number of medicinal plants reported to have 
anti-HIV properties were subjected to 
phytochemical investigation which resulted in the 
discovery of anti-HIV drug candidates [1-4]. This 
process leads to substantial progress in the 
isolation of different classes of molecules 
possessing anti-HIV properties. Among various 
classes of natural products, terpenes have also 
been reported to possess anti-HIV activities. 
Betulinic acid, platanic acid and oleanolic acid 
abundant in the leaves of Syzigium claviflorum, 
exhibited anti-HIV activity in H9 lymphocyte cell 
[5-7]. To enhance the anti-HIV activity, oleanolic 
acid was subjected to structural modification for 
the development of more potent pharmacophore. 
Among the different analogs synthesized, 3- 
oxotirucalla-7,24-dien-21-oic acid (OTUA) 
(Figure 1) exhibited promising anti-HIV activity 
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compared to its parent molecule. OTUA showed 
inhibition of HIV protease with an IC50 value of 10 
mg/mL [8].  
 
The modulation of antigen-specific signalling on 
virtually all T cells in a ligand-independent 
manner is performed by group B cysteine-rich 
scavenger receptor CD5 [9-13]. The conjugation 
of T-cells with antigen-presenting cells is 
accompanied by co-localization of CD5 with T-
cell receptors (TCRs). This leads to involvement 
of cognate MHC/peptide complexes within the 
immunological synapse and engagement of SHP 
phosphatases to the area through its cytoplasmic 
tyrosine inhibitory motif (ITIM) [11,14]. Therefore, 
there is suppression of TCR-derived activation 
signals by the antagonism of phosphorylation 
events caused by CD5 [15]. Stronger interaction 
between TCR and MHC/peptide complex is 
expected when CD5 concentration is higher. 
Thus CD5 expression on a T-cells 
TCR/MHC/peptide complex interaction is 
required for T cell activation [16]. In the present 
study, we investigated the effect of oleanolic acid 
ester, 3-oxotirucalla-7, 24-dien-21-oic acid on the 
CD8+ T cell count in HIV-infection.  
 
 







The patients accessing 3-oxotirucalla-7, 24-dien-
21-oic acid treatment were studied at the 
Yunnan's Care Centre, Anning City, Southwest 
China's Yunnan Province. The study was 
approved by the Ethics Committee of the 
Yunnan's Care Centre (approval ref no. 
158/2014/YCC) and followed the guidelines of 
World Health Organisation (WHO) 2002 
recommendations [17]. The patients were treated 
free of charge. 3- Oxotirucalla-7, 24-dien-21-oic 
acid treatment was given to the patients with 
CD8+ T cell counts < 200 cells/μL daily without 
interruption. 
 
Materials and data collection 
 
Versant™ HIV-1 RNA 3.0 branched chain DNA 
assay (Bayer HealthCare, Leverkusen, 
Germany), was used to measure plasma HIV-1 
load at baseline and after every 4 months. Flow 
cytometry using FACSCount ™ (Becton 
Dickinson Inc., Franklin Lakes, NJ, USA), was 
used for blood CD8+ T cell counts. Patients’ 
records were maintained and transferred weekly 
to a computer database. At the end of the 
programme, the data were analysed. The study 
of these patients was approved by the Research 
Ethics Committee of the Yunnan's Care Centre. 
A written consent was obtained from all the 
patients enrolled, in order to ensure that they 
were aware of the type of study.  
 
Data analysis  
 
For the analysis of the data obtained, we used 
Stata version 9.0 (College Station, Texas, USA). 
The absolute responses in CD8+ T cell counts 
were calculated during the intervals (from 
baseline to 24 weeks of 3-oxotirucalla-7, 24-dien-
21-oic acid treatment, and 24 to 48 weeks). 
Increase in CD8+ T-cell count (cells/μl/month) 
during each interval was also calculated. The 
effects of 3-oxotirucalla-7,24-dien-21-oic acid 
treatment on CD8+ T-cell responses were  
observed in terms of CD8+ T cell count below 90 
%; achievement of CD8+ T-cell count of 90-95 % 
and CD8+ T-cell count above 95 % at 48 weeks. 
Wilcoxon rank-sum and sign-rank tests for 
comparison of medians and χ2 tests for 




Effect of HIV- infection on level of CD8+ T 
cells circulating with expression of CD5  
 
The results revealed that in HIV-positive patients, 
the proportion of CD8+ T-cells circulating with 
CD5 expression was significantly lower than 
those in the normal controls. The median level of 
CD8+ T-cells in the HIV-positive patients was 
89.5 with an interquartile range of 91.2-82.4 
versus 99.0 with interquartile range 98.7-99.8 (p 
< 0.0001, Mann Whitney test) in normal controls. 
Thus, HIV replication effectively suppressed 
CD8+ T cells which lead to decrease of CD5 
expression. 
 
Effect of 3- oxotirucalla-7,24-dien-21-oic acid 
on virological and CD8+ T cells response 
 
3- oxotirucalla-7, 24-dien-21-oic acid treatment 
led to a significant decrease in viral level at each 
follow-up time point. The viral load was 
decreased to < 350 copies per mL at each of the 
follow-up time-points (Table 1). We also 
observed a remarkable change in the level of 
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CD8+ T-cells in the blood of patients treated with 
3-oxotirucalla-7, 24-dien-21-oic acid for 48 weeks 
(Figure 2). Treatment for 48 weeks resulted 
percentage of HIV-positive patients having 
median level of CD8+ T-cells 89.5 was reduced 
to 1 % only (Table 1). 
While comparing the increase in CD8+ T cell 
count during two phases, we observed that rate 
of increase was faster during first phase of 24 







Figure 2: The frequency distribution of absolute blood CD8+ T cell counts (a) at baseline and (b) after 48 weeks 
of 3- oxotirucalla-7, 24-dien-21-oic acid treatment 
 
Table 1: Changes in blood CD8+ T cell counts and plasma viral load of patients (n = 50) during 3- oxotirucalla-7, 
24-dien-21-oic acid treatment 
 
Variable Baseline Week 24 Week 48 
Virological response 
Average VL 
Patients with VL ≥ 350 (No: and %) 













CD8+ T Cell count response 







VL = viral load (copies/µL) 
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Figure 3: Graph showing the median CD8+ T cell counts at baseline and during 3-oxotirucalla-7, 24-dien-21-oic 
acid treatment stratified by baseline CD8+ T cell count 
 
Effect of 3- oxotirucalla-7, 24-dien-21-oic acid 
with respect to baseline CD8+ T cell count  
 
Increase in CD8+ T-cell count during the phase 1 
(0-24 weeks) after 3- oxotirucalla-7,24-dien-21-
oic acid treatment was almost same irrespective 
of the base line cell count (Figure 3). However, 
phase 1 CD8+ T-cell recovery was found to be 
dependent on baseline plasma viral load. The 
phase 1 CD8+ T-cell slope was 13.6 
cells/µl/month in patients with baseline viral load 
< 5 log10 copies/µL. On the other hand, the 
slope was 24. 4 cells/µl/month among those with 
baseline viral load of > 5 log10 copies/ µL. 
 
During phase 2 (24-48 weeks), after 3-
oxotirucalla-7, 24-dien-21-oic acid treatment, the  
increase in CD8+ T cell count was greater among 
the patients with a baseline CD8+ T-cell count < 
90 cells/µL compared to those with higher 
baseline counts. The age of patients was also an 
important factor that influences the CD8+ T-cell 
count during phase 2. The rate of increase was 
also greater among younger compared to older 
patients. Therefore, both the low baseline CD8+ 
T-cell count and the younger age were the only 
baseline characteristics that were significantly 
associated with higher rates of phase 2 CD8+ T 
cell recovery. 
 
Baseline CD4 CD8+ T cell count and risk of 
immunological non-response 
 
After 48 weeks of 3- oxotirucalla-7, 24-dien-21-
oic acid treatment, the blood CD8+ T-cell count 
increased by < 50 cells/µL among 20 (9.7 %) 
patients; of these, the viral load was suppressed 
< 50 copies/mL among 4 % patients, 
representing a treatment discordance rate of 7 
%. Contrary to our initial hypothesis, low baseline 
CD8+ T-cell counts were not associated with 
increased risk of immunological non-response. 
Among patients with baseline CD8+ T-cell counts 
of < 50, 50–99, 100–149 and 150 cells/µL, the 
proportions of patients who were immunological 
non-responders were 5, 4, 11 and 19 %, 
respectively. Furthermore, in multivariate 
analyses, an increment of < 50 cells/µL was 
independently associated with higher baseline 
CD8+ T-cell count as well as older age, lower 
baseline viral load, and a viral load > 400 




The current study represents the first report to 
demonstrate the effects of 3-oxotirucalla-7, 24-
dien-21-oic acid (OTUA) treatment on CD8+ T-
cell count among patients suffering from HIV 
infection. The results revealed increased rates of 
CD8+ T-cell count recovery in the second phase 
(24 – 48 weeks) in patients having CD8+ T-cell 
concentration during baseline < 50 cells/μL. On 
the other hand, the rates of phase 1 (0 – 24 
weeks) recovery were similar, irrespective of 
baseline CD8+ T-cell counts. 3-oxotirucalla-7, 24-
dien-21-oic acid treatment led to increased 
response to CD8+ T-cell recovery in patients with 
low baseline counts. The increased response to 
enhance count of CD8+ T-cells by patients 
having baseline CD8+ T cells more than 50 
cells/μL, could not reach to the value of 200 
CD8+ T/μL at 48 weeks. 
 
Zhang et al 
Trop J Pharm Res, December 2015; 14(12): 2211  
 
Table 2: Change in blood CD8+ T cell count during anolignan A treatment using logistic regression models 
  
Variable Immumological non-respouse 
risk 
CD8+ T cell count of ≥ 200 
cells/μl risk 
OR (95% CI) P value OR (95% CI) P-value 
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3-Oxotirucalla-7, 24-dien-21-oic acid treatment 
resulted in decrease of percentage of patients 
with a CD8+ T-cell count < 100 cells/μL from 61 
% at baseline to 5 % at after 48 weeks. It has 
been reported that the patients with the lowest 
baseline CD8+ T-cell counts have higher death 
risks [26]. During phase 2, the sustenance of 
suppression of viral replication also has a key 
role in the CD8+ T-cell recovery [27,28]. In our 
study, the proportion of the patients having more 
than 50 D8+ T-cells/μL was only 6 % following 48 
week treatment with 3-oxotirucalla-7, 24-dien-21-
oic acid and 4 % were immunologically non-
responsive even after a marked reduction in viral 
level. Moreover, 23 % of 'super-responders' had 
baseline CD8+ T-cell counts < 50 cells/μL, 
indicating that a very low baseline CD8+ T-cell 
count does not preclude an excellent CD4 cell 
count response to 3-oxotirucalla-7, 24-dien-21-




The study revealed that patients with CD4 counts 
in the lower range have a significant tendency for 
immune recovery. 3-Oxotirucalla-7, 24-dien-21-
oic acid treatment suppresses the viral level and 
enhances the probability of immune system 
recovery. Therefore, 3-oxotirucalla-7, 24-dien-21-
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